Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
Palisade Bio (NASDAQ: PALI) has been selected to present at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit in Boston, MA from May 13-15, 2025. Dr. Joerg Heyer, Head of Translational Science and Medicine, will deliver an oral presentation titled "Improving Patient Subtyping with AI-Driven Insights to Unlock Better Insights into IBD Heterogeneity & Smash the Efficacy Ceiling" on May 13, 2025, from 9:30 AM to 10:00 AM ET.
The presentation falls under the session "Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes." The summit aims to explore advancements in precision medicine strategies and treatment development for IBD patients.
Palisade Bio (NASDAQ: PALI) è stata selezionata per presentare al 3° Summit Annuale sulla Medicina di Precisione nelle Malattie Infiammatorie Intestinali che si terrà a Boston, MA, dal 13 al 15 maggio 2025. Il Dr. Joerg Heyer, Responsabile della Scienza e Medicina Traslazionale, terrà una presentazione orale intitolata "Migliorare la sottotipizzazione dei pazienti con approfondimenti basati sull'IA per svelare una migliore comprensione dell'eterogeneità della MII e superare il limite di efficacia" il 13 maggio 2025, dalle 9:30 alle 10:00 ET.
La presentazione rientra nella sessione "Avanzare la diagnostica guidata dall'IA e migliorare il monitoraggio dei pazienti per personalizzare le decisioni terapeutiche e migliorare i risultati a lungo termine per i pazienti." Il summit mira a esplorare i progressi nelle strategie di medicina di precisione e nello sviluppo di trattamenti per i pazienti con MII.
Palisade Bio (NASDAQ: PALI) ha sido seleccionada para presentar en la 3ª Cumbre Anual de Medicina de Precisión en Enfermedad Inflamatoria Intestinal en Boston, MA, del 13 al 15 de mayo de 2025. El Dr. Joerg Heyer, Jefe de Ciencia Traslacional y Medicina, ofrecerá una presentación oral titulada "Mejorando la subtipificación de pacientes con conocimientos impulsados por IA para desbloquear mejores entendimientos sobre la heterogeneidad de la EII y superar el techo de eficacia" el 13 de mayo de 2025, de 9:30 a 10:00 AM ET.
La presentación forma parte de la sesión "Avanzando en diagnósticos impulsados por IA y mejorando el monitoreo de pacientes para personalizar las decisiones de tratamiento y mejorar los resultados a largo plazo." La cumbre tiene como objetivo explorar los avances en estrategias de medicina de precisión y desarrollo de tratamientos para pacientes con EII.
Palisade Bio (NASDAQ: PALI)가 2025년 5월 13일부터 15일까지 매사추세츠주 보스턴에서 열리는 제3회 연례 염증성 장질환 정밀의학 서밋에서 발표자로 선정되었습니다. 번역과학 및 의학 책임자인 Dr. Joerg Heyer가 2025년 5월 13일 오전 9시 30분부터 10시까지 "AI 기반 통찰력으로 환자 하위 유형 개선: IBD 이질성에 대한 더 나은 이해와 효능 한계 극복"이라는 제목의 구두 발표를 진행합니다.
이 발표는 "AI 기반 진단 진전 및 환자 모니터링 강화로 치료 결정 맞춤화 및 장기 환자 결과 개선" 세션에 포함되어 있습니다. 이번 서밋은 IBD 환자를 위한 정밀 의학 전략과 치료 개발의 최신 동향을 탐구하는 것을 목표로 합니다.
Palisade Bio (NASDAQ : PALI) a été sélectionnée pour présenter au 3e Sommet Annuel sur la Médecine de Précision dans les Maladies Inflammatoires Chroniques de l'Intestin à Boston, MA, du 13 au 15 mai 2025. Le Dr Joerg Heyer, responsable de la science translationnelle et de la médecine, donnera une présentation orale intitulée « Améliorer la sous-typification des patients grâce à des insights pilotés par l'IA pour mieux comprendre l'hétérogénéité de la MICI et dépasser le plafond d'efficacité » le 13 mai 2025, de 9h30 à 10h00 ET.
Cette présentation s'inscrit dans la session « Faire progresser les diagnostics pilotés par l'IA et améliorer le suivi des patients pour personnaliser les décisions de traitement et améliorer les résultats à long terme ». Le sommet vise à explorer les avancées dans les stratégies de médecine de précision et le développement de traitements pour les patients atteints de MICI.
Palisade Bio (NASDAQ: PALI) wurde ausgewählt, auf dem 3. Jahrestreffen für Präzisionsmedizin bei entzündlichen Darmerkrankungen in Boston, MA, vom 13. bis 15. Mai 2025 zu präsentieren. Dr. Joerg Heyer, Leiter Translational Science and Medicine, wird am 13. Mai 2025 von 9:30 bis 10:00 Uhr ET einen Vortrag mit dem Titel "Verbesserung der Patientensubtypisierung durch KI-gestützte Erkenntnisse zur besseren Erfassung der Heterogenität von IBD und Überwindung der Wirksamkeitsgrenze" halten.
Die Präsentation gehört zur Sitzung "Fortschritte bei KI-gesteuerten Diagnosen und verbesserte Patientenüberwachung zur Personalisierung von Behandlungsentscheidungen und Verbesserung der langfristigen Patientenergebnisse." Der Gipfel zielt darauf ab, Fortschritte in Präzisionsmedizinstrategien und der Entwicklung von Behandlungen für IBD-Patienten zu erkunden.
- None.
- None.
Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA.
Details of the oral presentation are as follows:
Session: Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes
Title: Improving Patient Subtyping with AI-Driven Insights to Unlock Better Insights into IBD Heterogeneity & Smash the Efficacy Ceiling
Presenter: Joerg Heyer, Ph.D., Head of Translational Science and Medicine at Palisade
Session Date & Time: May 13, 2025 from 9:30 AM to 10:00 AM ET
The 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit provides a unique platform to explore groundbreaking advancements, refine precision medicine strategies, and drive the development of transformative treatments - ensuring the right drug reaches the right patient, at the right time. For more information about the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit, please visit the summit website.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company’s current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company’s product candidates, and its ability to serve those markets, including any potential revenue generated; the Company’s ability to maintain the Nasdaq listing of its securities; the Company’s ability to compete effectively in a competitive industry; the Company’s ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company’s ability to enter into commercial supply agreements; the Company’s ability to attract and retain key scientific or management personnel; the accuracy of the Company’s estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company’s business, and operations, and supply. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What will Palisade Bio (PALI) present at the 2025 IBD Summit?
When and where is the 3rd Annual Precision Medicine in IBD Summit 2025?
Who is presenting for Palisade Bio (PALI) at the 2025 IBD Summit?
What is the focus of Palisade Bio's (PALI) research in IBD?
